The EVIS X1™ is the most advanced endoscopy system from Olympus. It is designed to optimise the early detection, characterisation, and treatment of gastrointestinal diseases. By combining high-definition imaging with innovative visualisation technologies, it supports physicians in making precise diagnoses and efficiently performing minimally invasive procedures directly within the endoscopy suite.

Artificial intelligence (AI) assists clinicians by analysing endoscopic video feeds in real time, helping to highlight subtle tissue anomalies and potential lesions that can be difficult to detect during routine screenings. This continuous digital support enhances diagnostic accuracy, standardises procedure quality, and assists cognitive workload for medical teams.

Olympus integrates this technology through OLYSENSE™, a cloud-based AI platform that hosts a scalable portfolio of clinical applications. Designed to seamlessly fit into the modern endoscopy suite, it provides real-time decision support during gastrointestinal examinations to assist physicians in making confident, early-stage clinical decisions.

Narrow Band Imaging™ (NBI™) utilises specific wavelengths of light to enhance the visual contrast of surface vessels and mucosal morphology. Texture and Color Enhancement Imaging™ (TXI™) complements this by optimising the appearance of lesions through improved texture, brightness, and color. Together, these technologies facilitate the optical biopsy and the precise demarcation of neoplastic tissue.

Learn more about NBI™

The EUS portfolio combines high-performance ultrasound processors with linear and radial echoendoscopes. These systems provide detailed visualisation of the gastrointestinal wall layers and adjacent anatomical structures. This supports high precision in EUS-guided Fine Needle Aspiration (FNA) and Fine Needle Biopsy (FNB) for definitive histological diagnosis.

To ensure patient safety and the longevity of the equipment, Olympus provides a validated reprocessing cycle. This includes automated endoscope reprocessors that adhere to stringent international standards, as well as specialised cleaning chemistry and single-use valves. These solutions minimise cross-contamination risks and optimise the workflow in endoscopy departments with high patient turnover.

The ScopeGuide operating instructions explicitly advise against using ScopeGuide on pregnant women or in close proximity to them.

However, to assist you in any risk assessment you may be required to perform, Olympus has conducted separate testing with the endoscope, the position-detecting probe (MAJ-1878), the reference plate (MAJ-1860), or the hand coil (MAJ-1859) when connected to ScopeGuide (UPD-3). The magnetic flux density is close to 0 nT when the above equipment is 60 cm away from the measurement instrument and approximately 250 nT when the distance is 0 cm. Please note that due to the characteristic of the magnetic flux density, Olympus is unable to determine the exact distance at which the magnetic flux density becomes zero.

Please note that neither Olympus Medical, Olympus Corporation Ltd, KeyMed (Medical & Industrial Equipment) Ltd, nor any authorised representatives of Olympus can accept liability or responsibility if an adverse incident occurs due to using ScopeGuide near pregnant women or staff suspected of being pregnant.

The ScopeGuide operating instructions explicitly advise against using ScopeGuide on patients with a critical active implantable device, such as a pacemaker and an implantable cardioverter defibrillator.

The use of magnetic field-generating devices adjacent to, or in the vicinity of, a pacemaker or ICD should be avoided due to their construction. Please note that the response of the device to any magnetic field will be dependent on how it has been programmed for that specific patient.

For some pacemakers, subjecting the device to a magnetic field may result in asynchronous pacing, whilst in others, a period of device diagnostics is initiated, after which pacing is resumed. Devices with depleted batteries may experience pacing instability and, in severe cases, cease to provide paced output. Exposing a pacemaker or ICD to a magnetic field will not necessarily modify or suspend pacing, but it may.

On this basis, it is strongly advised to contact the Cardiac Department responsible for implanting the device or the manufacturer for further advice and guidance.

To assist the Cardiac Department or the manufacturer, Olympus has conducted separate testing with the endoscope, the position-detecting probe (MAJ-1878), the reference plate (MAJ-1860), or the hand coil (MAJ-1859) when connected to ScopeGuide (UPD-3). The magnetic flux density is close to 0 nT when the above equipment is 60 cm away from the measurement instrument and approximately 250 nT when the distance is 0 cm. Please note that due to the characteristic of the magnetic flux density, Olympus is unable to determine the exact distance at which the magnetic flux density becomes zero.

Please note, no testing has been carried out by Olympus, and therefore neither Olympus Medical, Olympus Corporation Ltd, nor KeyMed (Medical & Industrial Equipment) Ltd, nor any person or persons authorised to represent Olympus can accept any liability or responsibility in the event of an adverse incident occurring as a result of use of the ScopeGuide on any patient fitted with a pacemaker or ICD.